Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Sales and Divestitures (2016 - 2022)

Arrowhead Pharmaceuticals (ARWR) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $931063.0 as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Gains from Sales and Divestitures rose 13.05% year-over-year to $931063.0, compared with a TTM value of $931063.0 through Mar 2022, up 13.05%, and an annual FY2021 reading of $899025.0, down 22.42% over the prior year.
  • Gains from Sales and Divestitures was $931063.0 for Q1 2022 at Arrowhead Pharmaceuticals, up from $263700.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.2 million in Q1 2019 and bottomed at $263700.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $1.1 million, with a median of $955404.0 recorded in 2020.
  • The sharpest move saw Gains from Sales and Divestitures surged 6489.59% in 2018, then tumbled 56.52% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $658959.0 in 2018, then dropped by 19.06% to $533333.0 in 2019, then plummeted by 47.44% to $280325.0 in 2020, then dropped by 5.93% to $263700.0 in 2021, then surged by 253.08% to $931063.0 in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for ARWR at $931063.0 in Q1 2022, $263700.0 in Q4 2021, and $899025.0 in Q3 2021.